Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1991:19 Suppl 1:S38-46.
doi: 10.1007/BF01644734.

[Cartilage-damaging effect of quinolones]

[Article in German]
Affiliations
Review

[Cartilage-damaging effect of quinolones]

[Article in German]
R Stahlmann. Infection. 1991.

Abstract

The cartilage damaging effect of quinolones on juvenile experimental animals represents an unusual effect which is unknown, in this form, for other classes of substances. Since the damage is manifested at quite low doses the manufacturers and regulatory agencies have taken the consequence of declaring these preparations counter-indicated for children and adolescents up to the end of the growing period. Motor disturbances were observed only rarely, and only in individual cases, seen after therapeutic use of these drugs for the treatment of bacterial infections. In spite of long-term and sometimes high dose treatment with nalidixic acid during the 1960s and 1970s (the arthropathogenic effect on dogs was first described in 1977) no joint alterations could be demonstrated clinically or by x-ray. From this conclusion can be drawn that the effects seen in animal experiments under therapeutic conditions do not occur with the same intensity in humans. But, since many questions concerning this unusual toxic potential are still unanswered, quinolones continue to be counter-indicated for patients who are in the growing phase. Further experimental data and clinical observations are necessary to exclude with certainty the possible danger of joint damage to young patients. Even today it is still unclear whether the generally favourable clinical observations made with nalidixic acid also hold true for the other quinolones and whether differences in the possible risks exist. It will only become possible to define, with the necessary amount of certainty, indications for the use of quinolones in pediatrics when further information is available.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Toxicol Appl Pharmacol. 1979 Oct;51(1):177-87 - PubMed
    1. Lancet. 1985 Mar 16;1(8429):646 - PubMed
    1. Lancet. 1988 Oct 15;2(8616):900 - PubMed
    1. Br Med J (Clin Res Ed). 1987 Sep 19;295(6600):699 - PubMed
    1. Infection. 1987 May-Jun;15(3):165-8 - PubMed

LinkOut - more resources